Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for patients with wild-type KRAS metastatic colorectal cancer (mCRC), following a successful re-examination procedure by Amgen.

"This opinion, for which a final European Commission decision is pending, is a welcome step forward and one that may lead to additional treatment options for patients facing an aggressive disease with limited treatment options," said Willard H. Dere, M.D., senior vice president and international chief medical officer at Amgen. "Studies have shown that patients taking Vectibix in combination with chemotherapy have a greater chance of living longer without their disease getting worse, in a landscape where few targeted agents have been shown to be effective when used with chemotherapy."

Data from studies 20050203 (PRIME) and 20050181 ('181) showed that adding Vectibix to either FOLFOX or FOLFIRI chemotherapy improved progression-free survival (PFS) versus chemotherapy alone for patients with wild-type KRAS mCRC. Additionally, the overall response rate (ORR) of Vectibix plus chemotherapy was higher than chemotherapy alone. Although numerically greater, the improvement in median overall survival (OS) did not achieve statistical significance in the Vectibix arm of either trial.(i)

The PRIME study evaluated Vectibix (6.0 mg/kg every two weeks) plus FOLFOX versus FOLFOX alone in patients with wild-type KRAS mCRC and found that V
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... Fla. Exciting new work by a Florida State ... system that can take your temperature, emit white light, ... And, the molecule looks like a butterfly. , Biwu ... Biomedical Engineering in the FAMU-FSU College of Engineering, created ... but has continued to discover that his creation has ...
(Date:8/28/2014)... 28, 2014 PrimeSource Building Products, ... selected SoundConnect to support their communication ... audio and web conferencing platform GlobalMeet powered by ... employees’ needs. SoundConnect delivers award winning “results ... Building Products will be utilizing GlobalMeet powered ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... , , OMAHA, Neb., Aug. 12 Transgenomic Inc. (OTC Bulletin ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... to the web at the, ...
... , SAN DIEGO, Aug. 12 Imagenetix, ... second study conducted on its proprietary compound, 1-TDC, for the treatment ... University, Department of Periodontology and Oral Biology, led the investigative team. ... of Periodontology and is also available online at: ...
... ATLANTA, Aug. 12 CryoLife, Inc., (NYSE: ... cardiovascular tissue processing company, today announced that it has ... Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac ... SynerGraft technology designed to remove allogeneic donor cells and ...
Cached Biology Technology:Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 2Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 3CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:8/28/2014)... mobile app called TX Invasives is now available from ... of Texas at Austin for identifying harmful non-native plant, ... species in the United States cause about $137 billion ... agricultural crops, clog waterways, kill native plants and more. ... app for reporting where invasive species occur, we,re more ...
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2
... highly exposed to common environmental chemicals - polyfluoroalkyl compounds ... and larger at 20 months of age, according to ... Health published online in the August 30 edition of ... in the production of fluoropolymers and are found widely ...
... leading a four-year federal research effort to evaluate freshwater ... recommendations on what can be done to make the ... population growth and the effects of climate change over ... and the University of Georgia are also part of ...
... their condition involves much more than adhering to a ... entails carefully monitoring the ongoing toll this disease takes ... diagnostic tool created by Columbia University researchers and reported ... Biomedical Optics Express may soon make it easier ...
Cached Biology News:Chemical exposure in the womb from household items may contribute to obesity 2NC State leads national effort to evaluate fresh water sustainability in the southern US 2Shedding new light on one of diabetes' most dangerous complications 2
... Bio luciferase assay. Mo Bio Laboratories offers the ... you to certify your products ATP-Free with a ... deliver them to your customers in a timely ... 3.5 x 10-12 /l, which will allow you ...
... Sciences provides a comprehensive microarray service ... RNA embedded within non-coding RNAs (ncRNAs) ... proprietary probe design, which enables highly ... small RNAs (1). This comprehensive service ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... of all human, mouse, and rat ... Genomewide, predesigned siRNAs for a direct ... Ready-to-use, convenient matching solutions for SYBR ... Cost-effective RNAi and downstream analysis ...
Biology Products: